- Home
- VCYT vs IBRX Comparison
VCYT vs IBRX Comparison
Compare VCYT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- IBRX
- Stock Information
- Founded
- VCYT 2006
- IBRX 2014
- Country
- VCYT United States
- IBRX United States
- Employees
- VCYT N/A
- IBRX N/A
- Industry
- VCYT Medical Specialities
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VCYT Health Care
- IBRX Health Care
- Exchange
- VCYT Nasdaq
- IBRX Nasdaq
- Market Cap
- VCYT 2.1B
- IBRX 2.3B
- IPO Year
- VCYT 2013
- IBRX N/A
- Fundamental
- Price
- VCYT $23.59
- IBRX $3.00
- Analyst Decision
- VCYT Buy
- IBRX Strong Buy
- Analyst Count
- VCYT 9
- IBRX 5
- Target Price
- VCYT $39.89
- IBRX $11.40
- AVG Volume (30 Days)
- VCYT 996.0K
- IBRX 6.8M
- Earning Date
- VCYT 08-06-2025
- IBRX 08-11-2025
- Dividend Yield
- VCYT N/A
- IBRX N/A
- EPS Growth
- VCYT N/A
- IBRX N/A
- EPS
- VCYT 0.41
- IBRX N/A
- Revenue
- VCYT $463,393,000.00
- IBRX $31,222,000.00
- Revenue This Year
- VCYT $12.55
- IBRX $567.98
- Revenue Next Year
- VCYT $9.79
- IBRX $160.56
- P/E Ratio
- VCYT $57.33
- IBRX N/A
- Revenue Growth
- VCYT 23.42
- IBRX 10238.41
- 52 Week Low
- VCYT $19.73
- IBRX $1.83
- 52 Week High
- VCYT $47.32
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- VCYT 34.13
- IBRX 59.41
- Support Level
- VCYT $22.61
- IBRX $2.64
- Resistance Level
- VCYT $27.91
- IBRX $2.94
- Average True Range (ATR)
- VCYT 1.05
- IBRX 0.17
- MACD
- VCYT -0.25
- IBRX 0.02
- Stochastic Oscillator
- VCYT 18.51
- IBRX 87.06
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.